002513.SZ
Jiangsu Lanfeng Biochemical Co., Ltd.
SZSE · Basic Materials · C 制造业 · CN
CNY 5.26
−1.50%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.5B | 2.3B | 1.8B | 1.7B | 1.4B |
| Cost of Revenue | 2.3B | 2.3B | 1.8B | 1.8B | 1.4B |
| Gross Profit | 100.4M | 73.3M | (38.4M) | (35.7M) | 9.4M |
| Operating Expenses | |||||
| R&D Expense | 53.3M | 63.1M | 68.7M | 15.3M | 11.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 109.3M | 90.6M | 84.7M | 142.7M | 90.7M |
| Selling & Marketing Expense | 54.9M | 57.1M | 45.6M | 25.2M | 13.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 288.1M | 276.2M | 261.4M | 217.9M | 128.5M |
| Cost and Expenses | 2.6B | 2.5B | 2.1B | 2.0B | 1.6B |
| Operating Income (EBIT) | (273.5M) | (284.1M) | (403.6M) | (346.7M) | (180.5M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (283.5M) | (290.1M) | (434.8M) | (354.3M) | (247.0M) |
| Income Tax Expense | (20.8M) | (18.3M) | (81.6M) | (6.6M) | 73.7M |
| Bottom Line | |||||
| Net Income | (183.2M) | (190.5M) | (252.5M) | (332.3M) | (320.7M) |
| Earnings from Cont. Ops | (262.8M) | (271.8M) | (353.2M) | (347.7M) | (320.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (183.2M) | (190.5M) | (252.5M) | (332.3M) | (320.7M) |
| Per Share | |||||
| Basic EPS | (CN¥0.49) | (CN¥0.51) | (CN¥0.68) | (CN¥0.89) | (CN¥0.86) |
| Diluted EPS | (CN¥0.49) | (CN¥0.51) | (CN¥0.68) | (CN¥0.89) | (CN¥0.86) |
| Revenue Per Share | CN¥6.54 | CN¥6.24 | CN¥4.86 | CN¥4.67 | CN¥3.86 |
| Shares | |||||
| Basic Shares Outstanding | 374.8M | 375.3M | 368.7M | 372.9M | 373.9M |
| Diluted Shares Outstanding | 374.8M | 375.3M | 368.7M | 372.9M | 373.9M |
| Profitability Metrics | |||||
| EBITDA | — | (142.4M) | (280.6M) | (248.9M) | (85.2M) |
| D&A | — | 141.7M | 123.0M | 97.8M | 95.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026